At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 16 enrolled
Drug / intervention
Rivipanseldrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 1, Non-randomized, Open-label, Parallel-group Single-dose Study To Evaluate The Pharmacokinetics, Safety, And Tolerability Of Intravenous Rivipansel (Pf-06460031) In Subjects With Moderate Hepatic Impairment And In Healthy Subjects With Normal Hepatic Function
In Brief
A Phase 1 clinical trial evaluating Rivipansel for Moderate Hepatic Impairment and Normal Hepatic Function. Completed, enrolled 16 participants across 1 site.
Detailed Summary
The purpose of this study is to determine the effect of hepatic impairment on rivipansel PK and safety.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesUnited States
Collaborators--
Timeline
Phase 1CompletedFinished
2017201820192020202120222023202420252026
First PostedAug 2016
Enrollment StartSep 2016
Primary CompletionFeb 2017
Study CompletionMar 2017
TodayJul 2026
First PostedAug 18, 2016
Enrollment StartSep 1, 2016
Primary CompletionFeb 1, 2017
Study CompletionMar 1, 2017
TodayJul 2, 2026
Enrollment to primary: 5 monthsPosted 9.9 years ago
Interventions
Rivipanseldrug
A single dose of IV Rivipansel over 20 minutes